Hubert H Fernandez

Summary

Affiliation: Rhode Island
Country: USA

Publications

  1. ncbi Treatment of psychosis in Parkinson's disease: safety considerations
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Drug Saf 26:643-59. 2003
  2. ncbi Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    J Clin Psychiatry 63:513-5. 2002
  3. ncbi Classification and treatment of tardive syndromes
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Neurologist 9:16-27. 2003
  4. ncbi Long-term outcome of quetiapine use for psychosis among Parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Mov Disord 18:510-4. 2003
  5. ncbi Atypical antipsychotics in Parkinson-sensitive populations
    Joseph H Friedman
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    J Geriatr Psychiatry Neurol 15:156-70. 2002
  6. ncbi Long-term outcome of clozapine use for psychosis in parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island, USA
    Mov Disord 19:831-3. 2004
  7. ncbi Hemiballismus from a parietal stroke in a Parkinson patient
    Motasem Al-Yacoub
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    Mov Disord 19:986-8. 2004
  8. ncbi Botulinum toxin type B for gait freezing in Parkinson's disease
    Hubert H Fernandez
    Department of Clinical Neuroscience, Brown University School of Medicine, Providence, RI, USA
    Med Sci Monit 10:CR282-4. 2004
  9. ncbi Parkinsonism in a nursing home: underrecognition
    Joseph H Friedman
    Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860, USA
    J Geriatr Psychiatry Neurol 17:39-41. 2004
  10. ncbi Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
    Expert Opin Investig Drugs 15:339-49. 2006

Collaborators

Detail Information

Publications52

  1. ncbi Treatment of psychosis in Parkinson's disease: safety considerations
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Drug Saf 26:643-59. 2003
    ..Electroconvulsive treatment is generally reserved for the patient with psychotic depression who is unable to tolerate any pharmacological therapy...
  2. ncbi Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    J Clin Psychiatry 63:513-5. 2002
    ..Most clinicians perceive psychosis in dementia with Lewy bodies (DLB) as more difficult to treat than Parkinson's disease, yet there are no reports comparing the antipsychotic response between the 2 disorders...
  3. ncbi Classification and treatment of tardive syndromes
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Neurologist 9:16-27. 2003
    ..Tardive syndromes are a group of delayed-onset abnormal involuntary movement disorders induced by a dopamine receptor blocking agent. There are several phenomenologically distinct types of TS...
  4. ncbi Long-term outcome of quetiapine use for psychosis among Parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Mov Disord 18:510-4. 2003
    ..6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07)...
  5. ncbi Atypical antipsychotics in Parkinson-sensitive populations
    Joseph H Friedman
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    J Geriatr Psychiatry Neurol 15:156-70. 2002
    ..Suggestions are made for future research to improve the interpretability of these studies...
  6. ncbi Long-term outcome of clozapine use for psychosis in parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island, USA
    Mov Disord 19:831-3. 2004
    ..Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine...
  7. ncbi Hemiballismus from a parietal stroke in a Parkinson patient
    Motasem Al-Yacoub
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    Mov Disord 19:986-8. 2004
    ..This suggests that HB itself, whether from a lesion in the subthalamic nucleus or elsewhere, is not what improves motor function in PD; instead, the physiological function of the damaged structure is the determining factor...
  8. ncbi Botulinum toxin type B for gait freezing in Parkinson's disease
    Hubert H Fernandez
    Department of Clinical Neuroscience, Brown University School of Medicine, Providence, RI, USA
    Med Sci Monit 10:CR282-4. 2004
    ..Freezing of Gait (FOG) can be a serious problem in Parkinson's disease (PD) and is usually refractory to medical treatment. Botulinum toxin (BTX) type A has been reported to relieve FOG in small open label studies...
  9. ncbi Parkinsonism in a nursing home: underrecognition
    Joseph H Friedman
    Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860, USA
    J Geriatr Psychiatry Neurol 17:39-41. 2004
    ..02). Only 1 patient with drug-induced parkinsonism and 3 residents with previously diagnosed Parkinson's disease had chart notes indicating that parkinsonism had been recognized...
  10. ncbi Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
    Expert Opin Investig Drugs 15:339-49. 2006
    ....
  11. ncbi REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3)
    Joseph H Friedman
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island 02860, USA
    Mov Disord 18:1520-2. 2003
    ..Our results support the previous observation that RBD-like behaviors are significantly increased in SCA-3...
  12. ncbi Monozygotic twins discordant for Huntington disease after 7 years
    Joseph H Friedman
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    Arch Neurol 62:995-7. 2005
    ..Huntington disease (HD) has only rarely been identified in identical twins. All described twins have had disease onset within 1 year of each other, suggesting that disease onset is determined solely by genetic influences...
  13. ncbi Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    Med Sci Monit 8:CR241-6. 2002
    ..Little is known about predictors of mortality among Parkinson patients living in long term care...
  14. ncbi What we have learned about sleep disorders and psychosis after nearly two centuries of Parkinson's disease. Summary and conclusions
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    CNS Spectr 13:34-5. 2008
  15. ncbi Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases
    Michael A Shapiro
    Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, P O Box 100236, Gainesville, FL 32610, USA
    Parkinsonism Relat Disord 12:392-5. 2006
    ..Social repercussions may prohibit patients and/or their families from volunteering such information...
  16. ncbi Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    Mov Disord 22:1061-8. 2007
    ..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
  17. ncbi When should levodopa therapy be initiated in patients with Parkinson's disease?
    Irene A C Halkias
    Department of Neurology, University of Florida, Gainesville, Florida 32608, USA
    Drugs Aging 24:261-73. 2007
    ..However, because of levodopa's superior efficacy, when a rapid and sustained symptomatic improvement is required because of significant motor disability, levodopa may be used as the first-line agent regardless of age...
  18. pmc Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
    Laura B Zahodne
    Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA
    CNS Spectr 13:26-33. 2008
    ..An emerging treatment option is acetylcholinesterase inhibitors. This article reviews what is currently known about the course, prognosis, and treatment strategies in Parkinson's disease psychosis...
  19. ncbi Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
    Hubert H Fernandez
    Movement Disorders Center, University of Florida, McKnight Brain Institute, Gainesville, FL 32610, USA
    Pharmacotherapy 27:174S-185S. 2007
    ..A third agent with MAO-B inhibition properties, safinamide, is in phase III development. Although not yet approved, safinamide may offer the added advantage of combined MAO-B and dopamine reuptake inhibition...
  20. ncbi Pearls in patient selection for deep brain stimulation
    Ramon L Rodriguez
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, Florida, USA
    Neurologist 13:253-60. 2007
    ..General neurologists and even general practitioners may be called upon to screen potential candidates for DBS. The patient selection process plays an important role in this procedure...
  21. doi Scales to assess psychosis in Parkinson's disease: Critique and recommendations
    Hubert H Fernandez
    Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, Florida 32611, USA
    Mov Disord 23:484-500. 2008
    ..The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time...
  22. ncbi Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Drugs Aging 24:663-80. 2007
    ..The favourable safety profile of rasagiline in the elderly and its once-daily formulation may maximise drug adherence and improve outcomes...
  23. ncbi The "chair test" to aid in the diagnosis of psychogenic gait disorders
    Michael S Okun
    Department of Neurology, University of Florida, McKnight Brain Institute, Gainesville, Florida 32610, USA
    Neurologist 13:87-91. 2007
    ..To evaluate the chair test for diagnosis of psychogenic gait disorders...
  24. ncbi Psychosis in Parkinson's disease
    Dylan P Wint
    Department of Psychiatry, McKnight Brain Institute University of Florida, Gainesville 32610, USA
    J Geriatr Psychiatry Neurol 17:127-36. 2004
    ..An emerging treatment option is the use of acetylcholinesterase inhibitors. This article reviews what is known about the epidemiology, risk factors, pathophysiology, and treatment of PD-related psychosis...
  25. ncbi Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease
    Deborah A Cahn-Weiner
    Memorial Hospital of Rhode Island and Brown Medical School, Pawtucket 02860, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:79-87. 2002
    ..To compare the cognitive and behavioral profiles of Alzheimer's disease (AD) and cognitively impaired patients with Parkinson's disease (PD) and to determine the individual measures that best discriminate the two patient groups...
  26. ncbi Pharmacotherapy of dementia with Lewy bodies
    Hubert H Fernandez
    Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, USA
    Expert Opin Pharmacother 4:2027-37. 2003
    ....
  27. ncbi Rationale for current therapies in Parkinson's disease
    Janet Romrell
    University of Florida, Department of Neurology, McKnight Brain Institute, PO Box 100236, Gainesville, FL 32610, USA
    Expert Opin Pharmacother 4:1747-61. 2003
    ..Even though there have been great advances in the medical options for symptomatic management of PD, there are still many unmet needs for this patient population...
  28. ncbi Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease
    Hubert H Fernandez
    Department of Neurology, University of Florida McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610, USA
    Mov Disord 20:104-5. 2005
    ..After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses...
  29. ncbi Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers
    Michael S Okun
    Department of Neurology, University of Florida, Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Arch Neurol 62:1250-5. 2005
    ..An attempt is made herein to evaluate the reasons for DBS failure in a series of such patients and to make recommendations to improve overall DBS outcomes...
  30. ncbi Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation
    Janel Johnson
    Laboratory of Neurogenetics, National Institute on Aging, Porter Neuroscience Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Neurodegener Dis 4:386-91. 2007
    ..Recently, mutations in LRRK2 encoding the protein dardarin have been linked to an autosomal dominant form of parkinsonism...
  31. ncbi Apomorphine therapy in Parkinson's disease: a review
    Ihtsham Ul Haq
    Movement Disorders Program, University of Florida, Department of Neurology McKnight Brain Institute, 100 S Newell Drive, PO Box 100236, Gainesville, Florida 32610 0236, USA
    Expert Opin Pharmacother 8:2799-809. 2007
    ..In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' states in Parkinson's disease, with a focus on intermittent subcutaneous administration...
  32. ncbi Unrecognized parkinsonism in acute care medical patients receiving neurological consultations
    Joseph H Friedman
    J Gerontol A Biol Sci Med Sci 58:94-5. 2003
  33. ncbi Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease
    Christopher Kenney
    Expert Rev Neurother 7:585-9. 2007
  34. ncbi Taking a closer look at sleep problems and psychosis in Parkinson's disease. Introduction
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL 32610, USA
    CNS Spectr 13:4-5. 2008
  35. ncbi 18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson disease
    Hubert H Fernandez
    Arch Neurol 59:1973; author reply 1973-4. 2002
  36. doi Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial
    Daniel Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, 9940 Talbert Ave 204, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 14:407-14. 2008
    ..The best balance of sustained efficacy and favorable safety profile was provided by 80 units of Dysport/eye in this study...
  37. doi Clinical cases where lesion therapy was chosen over deep brain stimulation
    Amanda K Hooper
    University of Florida, Movement Disorders Center, Gainesville, FL 32601, USA
    Stereotact Funct Neurosurg 86:147-52. 2008
    ..Lesion therapy represents a viable alternative and has several important advantages, including a decreased need for access to specialists and clinical follow-up, improved affordability, and a lower infection risk...
  38. ncbi Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience
    Hubert H Fernandez
    Department of Neurology, University of Florida College of Medicine, Gainesville, FL 32610
    Clin Neuropharmacol 27:4-5. 2004
    ..Our preliminary experience with aripiprazole is mixed but not very encouraging. Controlled studies are needed to evaluate aripiprazole in parkinsonian patients...
  39. ncbi Monamine oxidase inhibitors: current and emerging agents for Parkinson disease
    Hubert H Fernandez
    Movement Disorders Center, Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, FL 32610, USA
    Clin Neuropharmacol 30:150-68. 2007
    ..Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects...
  40. ncbi Identifying candidates for deep brain stimulation in Parkinson's disease: the role of the primary care physician
    Michael S Okun
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, USA
    Geriatrics 62:18-24. 2007
    ..Potential candidates who score well on this questionnaire can be referred for presurgical multidisciplinary evaluation at an experienced DBS implanting center...
  41. ncbi The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations
    Sonja W Scholz
    Molecular Genetics Unit, National Institute on Aging, National Institutes of Health, Building 35, Room 1A 1012, Bethesda, MD 20892, USA
    Neurosci Lett 395:227-9. 2006
    ..No association between genotypes in codon 129 and IPD was detected in three distinct populations, suggesting that this PRNP polymorphism has no direct influence on the susceptibility to IPD...
  42. ncbi Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study
    Michael S Okun
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Arch Neurol 63:729-35. 2006
    ..Previously, we reported that testosterone deficiency is more common in patients with PD compared with age-matched control subjects, and we also reported in 2 small open-label studies that some nonmotor symptoms responded favorably to TT...
  43. ncbi Diabetes mellitus among parkinsonian patients treated chronically with clozapine
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    Parkinsonism Relat Disord 10:439-41. 2004
    ..3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this...
  44. ncbi Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders
    Frank M Skidmore
    Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine in Gainesville, 32610, USA
    CNS Spectr 11:521-36. 2006
    ..Also discussed are the emerging targets, what is known about the cognitive sequelae of DBS, and what has been learned about the complications and therapeutic failures...
  45. ncbi Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia
    John Graff-Radford
    Department of Neurology, University of Florida Movement Disorders Center, University of Florida, Gainesville, FL, USA
    Arch Neurol 63:1181-4. 2006
    ....
  46. ncbi Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data
    Hon Chung Fung
    Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Neurol 5:911-6. 2006
    ....
  47. ncbi Laterality, region, and type of motor dysfunction correlate with cognitive impairment in Parkinson's disease
    Lindsy N Williams
    Department of Neurology, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Mov Disord 22:141-5. 2007
    ..22, t(105) = -1.95, P = 0.054. We therefore found that right-sided symptoms (for laterality), axial symptoms (for region), and bradykinesia (for type of symptoms) were the best predictors of cognitive function...
  48. ncbi Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease
    Ekaterina Rogaeva
    Centre for Research in Neurodegenerative Diseases and Division of Neurology, Department of Medicine, Toronto Western Hospital, University of Toronto, Ontario, Canada
    Arch Neurol 61:1898-904. 2004
    ..Mutations in the PTEN-induced kinase (PINK1) gene located within the PARK6 locus on chromosome 1p35-p36 have recently been identified in patients with recessive early-onset Parkinson disease...
  49. ncbi Deep brain stimulation and the role of the neuropsychologist
    Michael S Okun
    Department of Neurology, Movement Disorders Center, University of Florida, Gainesville, FL 32610, USA
    Clin Neuropsychol 21:162-89. 2007
    ..Additionally, this article will review all aspects of the DBS procedure that can result in mood, cognitive, and behavioral effects and what role(s) the neuropsychologist should play in screening and follow-up...
  50. ncbi Tardive dyskinesia
    Karla Soares-Weiser
    Enhance Reviews, Kfar Saba, Israel
    Semin Neurol 27:159-69. 2007
    ..None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention...
  51. ncbi Abnormal affective startle modulation in individuals with psychogenic [corrected] movement disorder
    Paul J Seignourel
    Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA
    Mov Disord 22:1265-71. 2007
    ..Abnormal affective startle modulation may be used to help distinguish between malingering and PMD. Future studies using larger samples are needed to better understand the role of emotions in conversion disorder...
  52. doi Distribution of motor impairment influences quality of life in Parkinson's disease
    Kim C Stewart
    Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida 32611, USA
    Mov Disord 23:1466-8. 2008
    ..Patients with greater UE and LE motor impairments had lower QoL scores. However, LE impairments had a greater influence than UE impairments across all QoL measures...